Nalotimagene carmaleucel - MolMed

Drug Profile

Nalotimagene carmaleucel - MolMed

Alternative Names: Herpes simplex virus thymidine kinase (HSV-Tk) donor lymphocytes; HSV-Tk; TBI-0301; TK; TK cell therapy - MolMed; Zalmoxis

Latest Information Update: 05 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MolMed
  • Class Cell therapies; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies; Leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Leukaemia

Most Recent Events

  • 01 Mar 2018 Launched for Leukaemia (Adjunctive treatment) in Italy (IV)
  • 26 Feb 2018 Launched for Leukaemia (Adjunctive treatment) in Germany (IV) before February 2018
  • 25 Jul 2017 Dompe acquires license and distribution rights to thymidine kinase cell therapy in European Economic Area (EEA), and option rights for Australia, Switzerland and Turkey for Haematological malignancies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top